Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Jan 20, 2026

If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) — Quoin...

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study

Oct 28, 2025

Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study Target Current Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ Treatment Investigator’s Global Assessment (IGA)...

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Oct 21, 2025

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) —  Quoin Pharmaceuticals Ltd....

Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome

Sep 9, 2025

New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved Treatment ASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX)...

Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome

Aug 21, 2025

ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awareness campaign...

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

Aug 12, 2025

New Episode Highlights the Painful, Often Misunderstood Reality of Living with Netherton Syndrome and the Urgent Need for Effective Treatments ASHBURN, Va., Aug. 12, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a...